Results 181 to 190 of about 258,151 (309)

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Combining Multiparametric Magnetic Resonance Imaging and Prostate-Specific Antigen Density in Selecting Patients for Prostate Biopsy. [PDF]

Cureus
Derimachkovski G, Georgiev G, Draginov K, Petkov B, Rumenov V, Stoilov D, Tomov Y, Vasilev V, Yanev K.   +8 more
europepmc   +1 more source

Fiber‐type soft bioelectronics for wearable and implantable sensing and therapy

BMEMat, EarlyView.
Fiber‐type soft bioelectronics are emerging as versatile platforms for wearable and implantable health monitoring and therapeutic applications. These bioelectronics use organic and inorganic matrices combined with advanced fillers, which feature high conductivity, electrochemical sensitivity, softness, and biocompatibility.
Haneul Kim, Hak Yong Kim, Ja Hoon Koo, Gi Doo Cha, Dae‐Hyeong Kim, Hye Jin Kim   +5 more
wiley   +1 more source

From prostate specific antigen to genomic signatures: Advances in biomarkers for prostate cancer diagnosis and prognosis. [PDF]

Transl Oncol
Hamed NW, Elbeljihy HS, Hussin SA, Fouda RM, Oy EK, W Magar R.   +5 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer. [PDF]

Ther Adv Med Oncol
Bilen MA, Lowentritt BH, Burbage S, Patel C, Rossi C, Kinkead F, Wong G, Pilon D, Shore ND.   +8 more
europepmc   +1 more source

Marine silicon for biomedical sustainability

BMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han, Zhibo Yang, Wei Xia, Chengtie Wu   +3 more
wiley   +1 more source

Prostate-specific antigen velocity as a predictor of survival outcomes in patients with prostate cancer: a meta-analysis. [PDF]

Front Oncol
Cui F, Zhang Y, Liu Z, Zhou Y, Man C, Fan Y.   +5 more
europepmc   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

BMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu, Wanghua Liu, Shao Li   +13 more
wiley   +1 more source

Additional predictive value of systemic inflammation indices beyond prostate specific antigen density for clinically significant prostate cancer. [PDF]

BMC Urol
Sulhan H, Kalyenci B.
europepmc   +1 more source